UNSPSC 51314350: Chlorpheniramine/phenylephrine/pyrilamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.

UNSPSC 51314350 Chlorpheniramine/phenylephrine/pyrilamine is a Commodity code that covers antihistamine and decongestant combination pharmaceutical products and related over-the-counter remedies. State and local governments procuring under this code buy finished pharmaceutical products for distribution through community health programs, emergency response initiatives, pharmacy benefit systems, and general health services delivery. The issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances coordinating procurement across participating jurisdictions. Recent opportunities show governments buying both branded and generic formulations through competitive bidding processes, with vendors required to maintain FDA compliance, cGMP certification, Drug Supply Chain Security Act (DSCSA) compliance, and established relationships with authorized pharmaceutical wholesalers.

Geographic activity centers on Florida and Minnesota, with interstate coordination through multistate cooperative purchasing vehicles. Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure naloxone and drug deactivation systems (1,900 units and 800 systems annually) with quarterly deliveries and a response deadline of July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs, signaling upstream interest in alternative supply-chain models. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026, requiring vendors to certify cGMP and DSCSA compliance, maintain relationships with three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson), and accept a 3 percent administrative fee. Evaluation weighted price competitiveness at 75 percent, with contract awards effective July 1, 2026, and terms spanning two years plus optional extensions.